| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
EGFR (ErbB1/HER1), including sensitizing mutants (L858R, exon 19 deletion) and the T790M resistance mutant. Inhibition blocks receptor autophosphorylation, downstream MAPK and PI3K-AKT signaling, and proliferation of EGFR-dependent non-small cell lung cancer cells.
|
|---|---|
| ln Vitro |
Discrete IC50 values for EGFR-IN-58 against wild-type and mutant EGFR are not uniformly reported in public catalogs. The compound is characterized as an EGFR inhibitor, but quantitative potency data against specific EGFR mutants and selectivity over other kinases require confirmation from primary medicinal chemistry literature.
|
| ln Vivo |
Publicly available in vivo efficacy data for this specific compound are limited. EGFR inhibitors as a class produce tumor growth inhibition in EGFR-mutant non-small cell lung cancer xenograft models, but compound-specific pharmacokinetic, tolerability, and efficacy data for EGFR-IN-58 require confirmation from primary pharmacology studies.
|
| Enzyme Assay |
EGFR kinase inhibition is measured using recombinant EGFR kinase domain (wild-type or mutant) and a peptide substrate in the presence of ATP. Serial dilutions of compound are pre-incubated with the enzyme, and phosphorylation is detected with an anti-phosphotyrosine antibody or a fluorescence-based ADP detection system. IC50 values are derived from dose-response curves.
|
| Cell Assay |
EGFR-dependent cancer cells such as PC-9, HCC827, or H1975 are seeded in 96-well plates and treated with serial dilutions of EGFR-IN-58 for 72 hours. Cell viability is measured by ATP or tetrazolium assays, and IC50 values are calculated. EGFR autophosphorylation and downstream phospho-AKT and phospho-ERK are assessed by immunoblotting.
|
| Animal Protocol |
Xenograft studies use immunocompromised mice bearing subcutaneous EGFR-mutant non-small cell lung cancer tumors. Compound is formulated in a suitable vehicle and administered by oral or intraperitoneal routes at dose levels guided by tolerability and pharmacokinetic studies. Tumor volume is measured twice weekly, and tumor tissue is analyzed for EGFR phosphorylation, downstream signaling, and apoptosis.
|
| References |
| Molecular Formula |
C31H30FN7O
|
|---|---|
| Molecular Weight |
535.61
|
| Appearance |
Typically exists as solid at room temperature
|
| SMILES |
CN1CCN(CC1)C2=CC=C(C=C2)NC(C3=CN=CN=C3NC4=CC5=C(N(C=C5)CC6=CC(F)=CC=C6)C=C4)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8670 mL | 9.3352 mL | 18.6703 mL | |
| 5 mM | 0.3734 mL | 1.8670 mL | 3.7341 mL | |
| 10 mM | 0.1867 mL | 0.9335 mL | 1.8670 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.